Taltz ® (ixekizumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

Taltz® (ixekizumab): What are the differences between the new and old formulation?

The new citrate-free formulation is without buffers and contains sucrose as tonicity agent.

UK_cFAQ_IXE469_CITRATE_FREE_FORMULATION_DIFFERENCE
UK_cFAQ_IXE469_CITRATE_FREE_FORMULATION_DIFFERENCE
en-GB

Formulation differences

The new citrate-free formulation of ixekizumab

  • does not contain any buffer; that is, it is
    • citrate free and contains
    • sucrose (80 mg/mL) as the tonicity agent.1

The original formulation contains

  • sodium citrate dihydrate (5.11 mg/mL) and
  • citric acid anhydrous (0.51 mg/mL) as buffers and
  • sodium chloride (11.69 mg/mL) as the tonicity agent.1 

The ingredients are the same for both the pre-filled pen and syringe.1 Please also see  All Taltz ingredients for all ingredients.  

This medicinal product contains less than 1 mmol sodium (23 mg) per 80 mg dose, that is to say essentially “sodium-free”.2

Ixekizumab is contraindicated in patients with serious hypersensitivity to the active substance or to any of the excipients.2

 All Taltz ingredients 1

Ingredients

Original Formulation

New Citrate-free Formulation

Purpose of Ingredient

Ixekizumab (active ingredient)

80 mg

80 mg

Active ingredient

Polysorbate 80

0.30 mg

0.30 mg

Stabilizer

Sodium citrate dihydrate

5.11 mg

-

Buffer

Citric acid anhydrous

0.51 mg

-

Buffer

Sodium chloride

11.69 mg

-

Tonicity agent

Sucrose

-

80 mg

Tonicity agent/ stabilizer

Sodium hydroxide

-

q.s. to pH 5.7

pH adjustment

Water for injection

q.s. to 1.0 mL

q.s. to 1.0 mL

Solvent/ vehicle

Abbreviations: q.s. = quantity sufficient

References

1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2Taltz [summary of product characteristics]. Eli Lilly and Company (Ireland) Limited, Ireland

Date of Last Review: 08 December 2021


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request